Browse Category

Pharmaceutical News News 18 November 2025 - 12 December 2025

Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025)

Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025)

NEW YORK — December 12, 2025 — Applied Therapeutics, Inc. (NASDAQ: APLT) is in the spotlight after announcing a definitive agreement to be acquired by Cycle Group Holdings Limited (“Cycle”), a rare-disease-focused company that operates as Cycle Pharmaceuticals. The headline terms include a small upfront cash payment and a potentially meaningful (but uncertain) contingent value right (CVR) tied to future FDA approvals and sales milestones—setting up a high-volatility, event-driven setup for APLT stock as the market digests what’s “real” value versus what’s optionality. GlobeNewswire Below is a detailed roundup of what’s new as of 12/12/2025, why APLT stock moved, and
Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

As of December 9, 2025 Exicure, Inc. (NASDAQ: XCUR) has suddenly moved from obscure micro‑cap to front‑page biotech story. After the company reported positive topline Phase 2 data for its lead drug candidate burixafor in multiple myeloma at the 2025 ASH Annual Meeting on December 8, the stock exploded higher in after‑hours and pre‑market trading.Exicure+2Investing.com+2 Below is a comprehensive look at the latest trial results, recent financials, analyst and algorithmic forecasts, and the key risks around Exicure stock as of December 9, 2025. Exicure (XCUR) Stock Today: Price, Volume and Recent Performance Exicure shares have been extraordinarily volatile going into
Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences Ltd. (NASDAQ: WVE) just delivered one of the wildest biotech moves of 2025. On Monday, December 8, 2025, the stock rocketed after the company reported positive Phase 1 obesity drug data for WVE‑007 and simultaneously launched a $250 million equity offering. With the next U.S. trading session set to open on Tuesday, December 9, investors are trying to decide whether this is the beginning of a new obesity heavyweight—or a classic biotech spike that could retrace just as fast. Below is a concise, news-style wrap of everything that happened after the bell on December 8 and what
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories and deal-driven cash inflows. Arrowhead Pharmaceuticals, Inc.+2MarketBeat+2 The rally caps a stunning year in which Arrowhead stock has delivered a year‑to‑date return of roughly 270% and a one‑year gain in the 160–200% range, depending on the data provider, vastly outpacing
TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ: TNXP) has quietly turned into one of 2025’s wildest biotech stories: a tiny company that finally won U.S. FDA approval for a fibromyalgia drug after a 15‑year drought, launched it in the U.S., expanded the same molecule into major depressive disorder (MDD), and watched its stock price explode more than 10,000% over the last year. Tonix Pharmaceuticals Holding Corp.+2Fintel+2 As of the latest close on Friday, 5 December 2025, TNXP stock finished at $19.64, up 0.56% on the day, with after‑hours trading nudging it to $19.80. Over the past week, the share price jumped about 23%, and
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion, Inc. (NASDAQ: BMEA) is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib (formerly BMF‑219) can deliver durable blood‑sugar control many months after patients stop taking it. The new results, presented at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles, pushed Biomea Fusion’s stock higher on Friday and have reignited debate over whether this beaten‑down biotech could still be a high‑risk turnaround story. Nasdaq+1 As of Friday, December 5, Biomea Fusion shares were trading in the low‑$1 range, giving the company a market
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight. On December 3, 2025, the pharma giant’s share price jumped more than 6% intraday to around $51.32, extending a multi‑day rebound driven by a mix of clinical trial news, AI‑driven R&D milestones, and fresh analyst calls. StockAnalysis At the same time, investors are weighing sizable legal risks and an approaching patent cliff — making BMY one of the more eventful large‑cap healthcare stocks to watch into 2026. Below is a comprehensive, SEO‑friendly rundown of today’s Bristol-Myers Squibb stock news, forecasts, and analysis as of December 3, 2025. BMY Stock Price
CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

As of December 2, 2025, CVS Health Corporation (NYSE: CVS) finds itself in a classic “good news, bad headlines” moment: the stock has pulled back after a strong 2025 rally, the company agreed to a federal settlement over insulin-pen billing, and yet Wall Street’s forecasts still point to further upside. Below is a structured rundown of the latest price action, news, forecasts and analyses as of and since December 2, 2025. Share price on December 2, 2025: dip after a big year On Tuesday, December 2, 2025, CVS Health shares fell about 1.9%, closing at $77.62, even as the broader
DAX Today: German Stock Market Rebounds as Bayer Soars on Stroke-Drug Success — 24 November 2025

DAX Today: German Stock Market Rebounds as Bayer Soars on Stroke-Drug Success — 24 November 2025

Germany’s stock market started the new week with a relief rally on Monday, 24 November 2025. The DAX 40 clawed back part of last week’s heavy losses as investors cheered a double‑digit surge in Bayer shares and looked past another weak reading on German business sentiment. By mid‑afternoon in Frankfurt, the DAX was trading around 23,200 points, up roughly 0.5–0.7% on the day, after briefly moving above 23,300 earlier in the session. Deutsche Börse Group+2Investing.com+2 Medium‑sized and technology stocks joined the move: the MDAX, TecDAX and SDAX were all comfortably in positive territory, helped by broad gains across European markets. Deutsche Börse Group+1 The rebound followed the DAX’s worst week in months, when the
InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals Inc. (NASDAQ: INM) is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name. On Wednesday, INM shares closed at $1.23, down almost 16% on the day, before surging about 22% after hours to around $1.50.Benzinga That momentum rolled into Thursday’s pre‑market session, where multiple market data sources showed gains of roughly 20–26%, with INM changing hands in the $1.49–$1.55 range on unusually high volume.Benzinga+2RTTNews+2 As regular trading gets underway, real‑time quote providers still show
Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is back in the spotlight today after releasing positive top-line results from the first cohort of its FDA‑approved Phase I/IIa clinical trial for CMND‑100 in alcohol use disorder (AUD). The update lands just one day after the company highlighted a new Israeli patent filing for a non‑hallucinogenic depression therapy, and as a fresh equity offering is expected to close around today’s date. GlobeNewswire+2GlobeNewswire+2 The cluster of announcements is drawing intense trading interest. As of mid‑afternoon on November 18, CMND shares were changing hands around $0.27, after touching an intraday high near $0.39, on
Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Small-cap Israeli biotech rallies after reporting a decade-long cancer‑free outcome in advanced hepatocellular carcinoma and launching enrollment in a pivotal Phase III trial. Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF, TASE: CANF) jumped on Tuesday after the company reported a striking 9‑year overall survival with a complete response in an advanced liver cancer patient treated with its investigational drug Namodenoson, and confirmed that a pivotal Phase III trial in hepatocellular carcinoma (HCC) is now enrolling patients in multiple regions. GlobeNewswire+1 According to real‑time market data, Can-Fite’s American Depositary Receipts (ADRs) traded around $0.47 on November 18, up more than

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop